Search Results

Clarity Pharmaceuticals and PSI CRO AG have entered into an agreement and have commenced work towards Clarity’s Phase III diagnostic trial of SAR-bisPSMA in prostate cancer participants, CLARIFY 1.

Enovis Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System) for use with the Company’s STAR® total ankle replacement system.

Australia’s Department of Health has issued import permits for Optimi’s MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme

Masimo (NASDAQ: MASI) today announced the findings of a study published in Frontiers in Neuroscience in which Dr. Lichy Han and colleagues at Stanford University evaluated the ability of Masimo SedLine® brain function monitoring to assess the sedation levels of patients undergoing drug-induced sleep endoscopy (DISE) with dexmedetomidine – a sedative with numerous advantages.

ITM Isotope Technologies Munich SE announced that it has entered into a co-development and exclusive license agreement with the Paul Scherrer Institute, a leading Swiss research institute in the natural and engineering sciences, for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161.

TruTag Technologies, Inc. and Spinnaker Biosciences, Inc. today announced that they have entered into a strategic supply partnership for TruTag’s advanced nano-porous silica (pSi) particles to support the commercialization of Spinnaker’s new therapy for the treatment of age-related macular degeneration (AMD).

Australia’s largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD